European Patent Office to Grant MilliporeSigma’s Patent Application for CRISPR Technology

Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR Related patent application recently awarded in Australia; similar patents pending in other countries, favorable outcomes anticipated Billerica, Massachusetts, August 3, 2017 — MilliporeSigma today announced that the European Patent Office (EPO) has issued a “Notice of Intention to Grant” for MilliporeSigma’s... Read more

Agilent Acquires Powerful Next Generation Sequencing IP Portfolio

Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif.–(BUSINESS WIRE)–Jul. 24, 2017– Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population... Read more

Agilent Acquires Powerful Next Generation Sequencing IP Portfolio

Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif., July 24, 2017 Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies... Read more

Agilent Acquires Powerful Next Generation Sequencing IP Portfolio

Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif.–(BUSINESS WIRE)–Jul. 24, 2017– Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population... Read more

Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more

Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more

Join the Webinar on Novel Applications of Multiphoton Microscopy on Wednesday, July 12, 2017, 12:00 PM EDT

Adult Thy1-EYFP H line mouse, in vivo (cranial window). Excitatory pyramidal neurons in Layer 5 partly express EYFP. Courtesy of Dr. Masahiro Fukuda and Prof. Haruo Kasai, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan Advances in multiphoton microscopy instruments and technology are leading to unique insights... Read more

ENZO BIOCHEM REPORTS DELAWARE COURT RULING

NEW YORK, NY, June 29, 2017 – Enzo Biochem Inc. (NYSE: ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular... Read more